Systemic Immune-Inflammation Index Predicts Prognosis of Patients with Esophageal Squamous Cell Carcinoma: A Propensity Score-matched Analysis

Systemic immune-inflammation index (SII), based on peripheral lymphocyte, neutrophil, and platelet counts, was recently investigated as a prognostic marker in several tumors. However, SII

has not been reported in esophageal squamous cell carcinoma (ESCC). We evaluated the prognostic value of the SII in 916 patients with ESCC who underwent radical surgery. Univariate and

multivariate analyses were calculated by the Cox proportional hazards regression model. The time-dependent receiver operating characteristics (ROC) curve was used to compare the

discrimination ability for OS. PSM (propensity score matching) was carried out to imbalance the baseline characteristics. Our results showed that SII, PLR, NLR and MLR were all associated

with OS in ESCC patients in the Kaplan-Meier survival analysis. However, only SII was an independent risk factor for OS (HR = 1.24, 95% CI 1.01–1.53, P = 0.042) among these systemic

inflammation scores. The AUC for SII was bigger than PLR, NLR and MLR. In the PSM analysis, SII still remained an independent predictor for OS (HR = 1.30, CI 1.05–1.60, P = 0.018). SII is a

novel, simple and inexpensive prognostic predictor for patients with ESCC undergoing radical esophagectomy. The prognostic value of SII is superior to PLR, NLR and MLR.

Esophageal cancer is a common cancer worldwide. In China, it is the 3th leading cancer in incidence and 4th in mortality1. In 2015, there were 477,900 new cases and 375,000 deaths of

esophageal cancer in China1. Although the development of its multidisciplinary treatment, five-year overall survival (OS) for esophageal cancer is 15–35% and the prognosis remains poor2. The

two main pathological subtypes of esophageal cancer are squamous cell carcinoma and adenocarcinoma. In China, esophageal squamous cell carcinoma (ESCC) accounts for over 90% of cases3. The

7th edition American Joint Committee on Cancer tumor-node-metastasis (AJCC TNM) staging system is used to distinguish the prognosis among different risk groups of ESCC patients. However,

ESCC patients at the same TNM stage and received similar therapy usually had variable outcomes. Therefore, it is important to explore dependable prognostic factors.

In recent years, neutrophil, platelet and lymphocyte derived from the peripheral blood were significantly associated with tumor progression in various tumors4,5,6. Some indicators such as

neutrophil lymphocyte ratio (NLR) based on neutrophil and lymphocyte, platelet lymphocyte ratio (PLR) based on platelet and lymphocyte, and monocyte lymphocyte ratio (MLR) have emerged as

prognostic factors in many cancers, including ESCC7,8,9,10. These indicators only integrate two cells. Systemic immune-inflammation index (SII), based on peripheral lymphocyte, neutrophil,

and platelet counts, was recently investigated as a prognostic marker in several tumors including hepatocellular carcinoma11,12, colorectal cancer13 and small cell lung cancer14. However,

SII has not been reported in ESCC. In this study, we evaluated the prognostic value of SII in patients with ESCC who underwent radical surgery. We also explore whether SII has more

advantages to predict the survival of ESCC population than NLR or PLR. To increase statistical power and to further elaborate on the possible prognostic impact of SII, both Cox’s

proportional hazards model analysis as well as propensity score matching (PSM) were applied.

There were 696 males (76.0%) and 220 females (24.0%) with an age range of 37–84 years (median 60.0 years), of which 46 patients were well differentiated, 450 patients were moderately

differentiated, and 420 patients were poorly differentiated. According to the 7th AJCC standard, there were 168 patients at stage 0-I, 395 patients at stage II and 353 patients at stage III.

Other clinicopathological features are shown in Table 1. The median OS was 42 months (range, 3 to 146 months) and the rate of 3- and 5-year OS was 52.5% and 44.2%, respectively. Patients

with SII > 307 in complete datasets were more likely to be men (P = 0.022), poor differentiation (P = 0.004), advanced T stage (P  0.28. Based on the univariate analysis, sex, histological

grade, T stage, N stage, SII, PLR, NLR and MLR were identified as the significant prognostic factors (Table 3). It was found that SII, PLR, NLR and MLR were highly correlated and had the

same factors. There four separate multivariate models (SII, PLR, NLR and MLR) were run to avoid problems with the presence of multicollinearity. Multivariate analyses demonstrated that

histological grade, T stage, N stage, and SII were independent risk factors for OS (Table 3). Among SII, NLR, PLR and MLR, only SII was an independent risk factor for OS (HR = 1.24, 95% CI

1.01–1.53, P = 0.042). In addition, the discrimination ability of SII, PLR, NLR and MLR was compared by the AUC for OS. The AUC for SII was bigger than SII, NLR, PLR and MLR for predicting

survival in patients with ESCC in 3-years and 5-years (Fig. 2). It means SII is superior to NLR, PLR or MLR as a predictive factor in ESCC patients.

Kaplan–Meier survival curves for patients stratified based on (A) SII, (B) PLR, (C) NLR and (D) MLR in unmatched complete datasets.

Predictive ability of the SII was compared with PLR, NLR and MLR by ROC curves in 3-years (A) and 5-years (B).

Considered the sex, histological grade, T stage, N stage and AJCC TNM stage were imbalance between SII ≤ 307 and SII > 307 ESCC patients (Table 1), we applied a 1:2 PSM ratio to minimize

these differences. In the PSM analysis, we selected 253 patients from SII ≤ 307 group with matched pairings of the 506 SII > 307 patients using a nearest-neighbour algorithm. These

clinicopathological characteristics were balanced and evenly distributed between these groups (all P > 0.1) (Table 1). The Kaplan-Meier survival curves for the matched groups are shown in

Fig. 3. In the matched 759 patients’ survival analysis, median OS was 76 months for SII ≤ 307 ESCC patients and 43 months for SII > 307 ESCC patients. The 5-year survival was 55.4% in SII ≤ 

307 ESCC patients versus 44.9% in SII > 307 ESCC patients. In addition, the multivariate analyses showed SII still remained an independent predictor for OS (HR = 1.30, CI 1.05-1.60, P = 

0.018) (Table 4).

Kaplan-Meier-estimated overall survival distributions from matched datasets for SII ≤ 307 versus SII > 307.

Inflammation has been known as a hallmark feature of tumor15. The correlation between inflammation and tumor was first reported by Rudolf Virchow in 186316. Recently, accumulating evidence

has indicated that inflammation contributes to tumor development, progression and metastasis. Systemic inflammatory scores such as NLR, PLR and MLR have been found to be independent markers

of prognosis in a variety of cancers, including ESCC7,8,9,10. A novel systemic inflammation score-SII, based on neutrophil, platelet, and lymphocyte counts, was shown to be an independent

risk of recurrence and survival for hepatocellular carcinoma, small cell lung cancer, colorectal cancer and gastric cancer patients11,12,13,14,17. It was considered to be better than PLR and

NLR, and was associated with higher circulating tumor cells (CTCs) levels. In the present study, SII was confirmed to be a novel independent predictor of survival for patients with

resectable ESCC by a multivariable Cox regression analysis and PSM analysis. It was shown to be superior to NLR, PLR and MLR as a predictive factor in ESCC patients. Compared with other

prognostic factors, the inflammation-based prognostic scores are simple, inexpensive and routinely performed in clinical practice. Meanwhile, SII based on standard laboratory measurements of

total platelet, neutrophil, and lymphocyte counts is simple, inexpensive and routinely performed in clinical practice. Thus, there is a potential for SII to be used as a marker for

prognosis and treatment response surveillance.

Several potential mechanisms may be used to explain the prognostic values of SII in tumor. Cancer-mediated myelopoiesis has been recognised in the promotion of tumor angiogenesis, cell

invasion, and metastasis in recent years. In contrast with myelopoiesis during acute infection, stress, or trauma in which circulating immune cells are transient increase, cancer

myelopoiesis is associated with persistence of immature myeloid cells18. Firstly, neutrophils are not released from the bone marrow until mature ordinarily, however, in the context of

inflammation, they were triggered by secretion of cytokines and chemokines, such as interleukin-6 (IL-6), tumor necrosis factor (TNF) and myeloid growth factors19. These inflammatory

mediators enhance the invasion, proliferation, and metastasis of cancer cell, aid cancer cells to evade immune surveillance, and induce the resistance to cytotoxic drugs6,20. The elevated

neutrophils can also release plenty of nitric oxide, arginase, and reactive oxygen species (ROS), leading to T cell activation disorders21. Secondly, platelets can protect CTCs from shear

stresses during circulation, induce epithelial-mesenchymal transition, and promote tumor cell extravasation to metastatic sites4,22. Meanwhile, platelets and neutrophils have been reported

to promote adhesion and seeding of distant organ sites through secreting vascular endothelial growth factor (VEGF)5,11,23. Thirdly, lymphocytes can also secrete several cytokines, such as

IFN-γ and TNF-α, to control tumor growth and improve prognosis of cancer patients24, and the decreased lymphocyte count and function will impair cancer immune surveillance and defense6,24.

Based on the above theory, SII should be a more objective marker that reflects the balance between host inflammatory and immune response status than all the other systemic inflammation index

such as the PLR and NLR. In fact, our results confirmed that SII is indeed superior to PLR, NLR and MLR. In addition, many studies have confirmed that non-steroidal anti-inflammatory drugs

(NSAIDs) are associated with improved survival outcomes in patients with cancer, including esophageal cancer25,26. The patients with ESCC who have a high SII maybe especially benefit from

targeted anti-inflammatory with aspirin and non-steroidal anti-inflammatory drugs (NSAIDs).

Although our results demonstrated the prognostic value of SII in ESCC, there are still several limitations in this study. First, it should be noted that most patients with esophageal cancer

in China are squamous cell carcinoma, while the most esophageal cancer is adenocarcinoma in western. Therefore, the prognostic significance of SII needs to be validated in patients with

esophageal adenocarcinoma. Second, our study was a retrospective study, and there may be selection bias during retrospective data collection. However, we used PSM analysis which can minimize

group differences in the baseline characteristics. Third, the majority (77.8%) of patients enrolled in this study had dissected lymph nodes with  307), NLR (NLR ≤ 1.7, NLR > 1.7), PLR (PLR 

≤ 120, PLR > 120) and MLR (MLR ≤ 0.28, NLR > 0.28) were determined by using X-tile software (http://www.tissuearray.org/rimmlab)28.

Statistical analysis was conducted with SPSS 22.0 (SPSS, Chicago, IL), Graphpad Prism 6.01 (La Jolla, CA, USA) and R software 3.2.5 (http://www.r-project.org/) with MatchIt packages. The

correlations between the inflammation-based prognostic scores and clinicopathological characteristics were analyzed by the χ2 test. Correlation analysis is using Person’s correlation test.

Survival curves were plotted using the Kaplan-Meier method and compared using the log-rank test. Univariate and multivariate analyses were calculated by the Cox proportional hazards

regression model. The time-dependent receiver operating characteristics (ROC) curve was used to compare the discrimination ability for OS. PSM was carried out because of imbalance in the

baseline characteristics. PSM was done with a nearest-neighbour matching algorithm, allowing a maximum tolerated difference between propensity scores less than 30% of the propensity score

SD. A P value less than 0.05 was considered to be statistically significant unless otherwise specified.

How to cite this article: Geng, Y. et al. Systemic Immune-Inflammation Index Predicts Prognosis of Patients with Esophageal Squamous Cell Carcinoma: A Propensity Score-matched Analysis. Sci.

Rep. 6, 39482; doi: 10.1038/srep39482 (2016).

Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This work was supported by the National Natural Science Foundation of China (31570877 and 81301960).

Geng Yiting and Shao Yingjie contributed equally to this work.

Department of Oncology, The Third Affiliated Hospital of Soochow University, 185 Juqian Street, Changzhou, 213003, P.R. China

Yiting Geng, Danxia Zhu, Qi Zhou, Wenjie Zhou, Xuefeng Ni, Changping Wu & Jingting Jiang

Department of Radiation Oncology, The Third Affiliated Hospital of Soochow University, 185 Juqian Street, 213003, Changzhou, P.R. China

Department of Tumor Biological Treatment, The Third Affiliated Hospital of Soochow University, 185 Juqian Street, Changzhou, 213003, P.R. China

Y.T.G., C.P.W. and J.T.J. conceived and designed the study and helped to draft the manuscript. Y.J.S. performed the statistical analysis. D.X.Z., X.Z., Q.Z., W.J.Z. and X.F.N. performed the

data collection. All authors reviewed the manuscript.

This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons

license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to

reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

Anyone you share the following link with will be able to read this content: